Uganda has received its first 19,200 doses of Lenacapavir, a groundbreaking HIV prevention injection taken only twice a year, marking a major boost in the country’s fight against new infections. The shipment follows approval by the National Drug Authority (NDA) in January, clearing the drug for use after promising clinical trial results. The consignment was […]
Uganda has received its first 19,200 doses of Lenacapavir, a groundbreaking HIV prevention injection taken only twice a year, marking a major boost in the country’s fight against new infections.
The shipment follows approval by the National Drug Authority (NDA) in January, clearing the drug for use after promising clinical trial results. The consignment was donated by the Global Fund, which has committed USD 1.1 million to support its rollout.
Lenacapavir proved highly effective as pre-exposure prophylaxis, PrEP, in clinical trials involving adolescent girls and young women in Uganda and South Africa, groups considered among the most vulnerable to HIV infection. The Ministry of Health now plans to begin distributing the injectable next month, targeting districts with high HIV burden and high transmission rates.
But even before the rollout begins, concerns are emerging. Activists warn that the donation will only cover around 10,000 people, a drop in the ocean for a country recording nearly 1,000 new HIV infections every week.
Lenacapavir is intended for people at highest risk, including sex workers, boda boda riders, long-distance truck drivers, and individuals in HIV-discordant relationships. Without proper guidance, there are fears of misuse or overwhelming demand that could strain limited supplies.
Uganda has already introduced another long-acting injectable, Cabotegravir, but that option requires more frequent visits, starting with two injections four weeks apart, followed by doses every two months. In contrast, Lenacapavir is administered just twice a year, offering greater convenience for those who struggle with daily pills or repeated clinic appointments. The Global Fund plans to supply a total of 36,000 doses to nine health facilities in the first quarter of 2026, but whether that will be enough remains a pressing question.
